ReCode Therapeutics

Powering the future of genetic medicines through superior delivery

United States · $281.0M raised

Business Model
B2B
Total Funding
$281.0M
Last Round
$29.0M Venture RoundJan 2024
Rounds
5

About

ReCode is a clinical-stage genetic medicines company developing mRNA and gene correction therapies for cystic fibrosis and primary ciliary dyskinesia. Its Selective Organ Targeting lipid nanoparticle platform is designed to direct genetic medicines to organs, tissues, and cells beyond the liver. The company is advancing therapies intended to address genetically defined diseases where current treatment options are limited or absent.

Summary

ReCode Therapeutics is a Biotech company based in United States. It has raised $281.0M in total across 5 rounds, most recently a $29.0M Venture Round round in Jan 2024. Investors include Cystic Fibrosis Foundation, Bioluminescence Ventures and Amgen.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Venture RoundVenture RoundJan 2024
$29.0M

Sign up to see all 5 rounds

Seed through Venture Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ReCode Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/recode-therapeutics"><img src="https://indexed.vc/api/badge/company/recode-therapeutics" alt="ReCode Therapeutics on Indexed.vc" width="260" height="76" /></a>